AZ-LIMELIGHT-NETWORKS
Limelight Networks, Inc. (Nasdaq: LLNW) , a leading provider of edge cloud services, today announced that MX Player used Limelight’s Content Delivery Network (CDN) to provide a seamless and a broadcast quality experience to millions of viewers watching the 2019 Lok Sabha Elections. More than 900 million Indian citizens were eligible to vote, making it the largest election in the world.
Investments over the last few years have helped Limelight emerge as one of the largest content delivery networks in the country. Limelight Networks has been working with MX Player and other content originators and distributors to address their global content delivery needs. The company delivers rich content such as video, games, and software into India for its global customers. At the same time, Limelight has been helping Indian media companies deliver content to their global customers.
At its peak, traffic was flowing at 10 times the normal volume during the election. Using Limelight’s CDN, MX Player handled anticipated traffic spikes and successfully managed to provide a seamless and broadcast-quality experience on millions of connected devices to their Indian and global customers.
"With 100 Million Daily Active Users and 275 Million Monthly Active Users, MX Player is the largest video platform from India. We partnered with Limelight Networks to deliver high performance video to our large user base. On May 23, the day elections results came out, we saw a 10x spike from our usual traffic trend. I’m very happy to see that the teams from both sides have integrated a really robust system, which was able to deliver billions of request on this day smoothly and successfully,” said Vivek Jain, Chief of Product, Tech & Operations, MX Player
“As a long time CDN and video delivery partner, Limelight Networks was honored for the opportunity to support this milestone event. We’ll continue to scale and innovate on our journey with MX Player and our other media customers and keep providing high quality services to their online audiences,” said Ashwin Rao, Director, India at Limelight Networks.
About MX Player:
With over 75 million Daily Active Users
(DAUs) – MX Player is the largest entertainment platform in the country,
present on 1 out of every 2 smartphones. Defining “everytainment” for
viewers with entertainment that suits every mood, it currently operates
on an ad supported model and is a free to use app for premium content.
MX Player provides users a wide online streaming library of over 100,000
hours of licensed content, across 10 languages and an exciting slate of
MX Original Series with genres ranging across drama, comedy, reality and
romance. From the stable of Times Internet (the digital venture of Times
of India, India's largest media and entertainment group), MX Player has
consistently ranked amongst the top 10 Android apps since 2012 and is
available across Android, iOS and Web.
About Limelight
Limelight Networks, Inc. (NASDAQ: LLNW), a
leading provider of digital content delivery, video, cloud security, and
edge computing services, empowers customers to provide exceptional
digital experiences. Limelight’s edge services platform includes a
unique combination of global private infrastructure, intelligent
software, and expert support services that enable current and future
workflows. For more information, visit www.limelight.com
,
follow us on Twitter
,
Facebook
,
and LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005570/en/
Contact:
SHIFT Communications Stephanie Epstein, 617-779-1845 Limelight@shiftcomm.com or Investor Inquiries: ir@limelight.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom